Pomerantz Law Firm Investigates Aardvark Therapeutics for Potential Securities Fraud
The Pomerantz Law Firm has launched an investigation into potential securities fraud involving Aardvark Therapeutics (NASDAQ: AARD). The firm is representing investors after the company voluntarily paused its Phase 3 HERO trial due to safety concerns and later faced a full clinical hold from the FDA. These events led to significant drops in stock price.
Tickers: $AARD
Topics: clinical_trial_pause securities_fraud stock_price_drop